Orion Portfolio Solutions LLC Purchases 3,936 Shares of Kenvue Inc. (NYSE:KVUE)

Orion Portfolio Solutions LLC raised its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 1.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 206,747 shares of the company’s stock after purchasing an additional 3,936 shares during the period. Orion Portfolio Solutions LLC’s holdings in Kenvue were worth $4,414,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of the business. Vanguard Group Inc. grew its stake in shares of Kenvue by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 218,543,705 shares of the company’s stock worth $4,665,908,000 after purchasing an additional 1,636,741 shares during the period. State Street Corp increased its stake in shares of Kenvue by 16.8% in the 3rd quarter. State Street Corp now owns 127,213,940 shares of the company’s stock valued at $2,942,458,000 after acquiring an additional 18,283,473 shares during the last quarter. Geode Capital Management LLC boosted its stake in Kenvue by 0.9% during the 3rd quarter. Geode Capital Management LLC now owns 44,677,077 shares of the company’s stock worth $1,029,810,000 after acquiring an additional 399,846 shares during the last quarter. Harris Associates L P increased its stake in Kenvue by 7.5% in the third quarter. Harris Associates L P now owns 31,459,511 shares of the company’s stock valued at $727,658,000 after purchasing an additional 2,186,114 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in Kenvue by 2.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 24,972,777 shares of the company’s stock worth $533,169,000 after purchasing an additional 561,570 shares during the period. Institutional investors own 97.64% of the company’s stock.

Kenvue Trading Up 1.0 %

Kenvue stock opened at $23.74 on Monday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The firm has a 50-day moving average of $22.32 and a 200-day moving average of $22.45. The company has a market cap of $45.36 billion, a price-to-earnings ratio of 44.78, a P/E/G ratio of 2.62 and a beta of 1.25. Kenvue Inc. has a one year low of $17.67 and a one year high of $24.46.

Kenvue (NYSE:KVUE) last issued its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. On average, equities analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were paid a $0.205 dividend. The ex-dividend date was Wednesday, February 12th. This represents a $0.82 annualized dividend and a yield of 3.45%. Kenvue’s dividend payout ratio (DPR) is currently 154.72%.

Analysts Set New Price Targets

KVUE has been the subject of a number of recent analyst reports. UBS Group lowered their price objective on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a research report on Friday, February 7th. Evercore ISI assumed coverage on Kenvue in a report on Monday, March 24th. They set an “in-line” rating and a $25.00 price objective on the stock. Royal Bank of Canada reissued a “sector perform” rating and set a $24.00 target price on shares of Kenvue in a research note on Monday, February 3rd. Citigroup dropped their target price on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a report on Wednesday, January 15th. Finally, Canaccord Genuity Group upped their price target on shares of Kenvue from $24.00 to $29.00 and gave the company a “buy” rating in a report on Wednesday, March 5th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $24.00.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.